Bausch Health Companies (BHC) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bausch Health Companies (BHC) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 3.8% versus a loss of 34.3%. Over five years, COLL leads with a +4.5% price change compared with -78.4% for BHC. Bausch Health Companies is the larger company by market cap ($2.28 billion vs $715.9 million), about 3.2 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.5x vs 3.3x for Collegium Pharmaceutical).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | COLL |
|---|---|---|
| Share price | $6.10 | $21.99 |
| Market cap | $2.28B | $715.90M |
| 1-day change | -0.81% | +0.27% |
| YTD return | -11.51% | -52.63% |
| 1-year return | -3.76% | -34.32% |
| 5-year return | -78.41% | +4.53% |
| P/E ratio (TTM) | — | 17.31 |
| Forward P/E | 1.45 | 3.31 |
| EPS (TTM) | $-2.95 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $50.79 |
| 52-week low | $4.33 | $21.43 |
| Distance from 52-week high | -23.75% | -56.70% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +22.95% | +122.83% |
| Average volume | 3.24M | 748.29K |
| Shares outstanding | 373.99M | 32.56M |
| Employees | 20,300 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch Health Companies is about 3.2 times larger than Collegium Pharmaceutical by market value ($2.28B vs $715.90M).
- BHC has outperformed COLL by 30.6 percentage points over the past year.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
BHC vs COLL FAQ
Which is bigger, Bausch Health Companies or Collegium Pharmaceutical?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.28B compared with $715.90M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, BHC or COLL?
BHC returned -3.76% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Collegium Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.